Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Breast Tissues”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03471663
What this trial is testing

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 200
Early research (Phase 1)Looking for participantsNCT05187832
What this trial is testing

AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC 61
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Large-scale testing (Phase 3)Study completedNCT04109066
What this trial is testing

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 521
Testing effectiveness (Phase 2)Looking for participantsNCT06369285
What this trial is testing

Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc. 225
Testing effectiveness (Phase 2)UnknownNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Early research (Phase 1)Active Not RecruitingNCT05537740
What this trial is testing

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bayer 129
Early research (Phase 1)Ended earlyNCT02628535
What this trial is testing

Safety Study of MGD009 in B7-H3-expressing Tumors

Who this might be right for
MesotheliomaBladder CancerMelanoma+10 more
MacroGenics 67
Testing effectiveness (Phase 2)Study completedNCT05412446
What this trial is testing

99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

Who this might be right for
Breast CancerFemale
Tomsk National Research Medical Center of the Russian Academy of Sciences 30
Early research (Phase 1)Ended earlyNCT00634088
What this trial is testing

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
R-Pharm 13
Early research (Phase 1)Study completedNCT03451162
What this trial is testing

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 14
Testing effectiveness (Phase 2)Study completedNCT01138384
What this trial is testing

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
NCIC Clinical Trials Group 19
Testing effectiveness (Phase 2)Study completedNCT04420598
What this trial is testing

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Who this might be right for
Advanced Breast CancerHER2-positive Breast CancerBrain Metastases+1 more
MedSIR 41
Early research (Phase 1)Study completedNCT00004604
What this trial is testing

Biological Therapy in Treating Patients With Metastatic Cancer

Who this might be right for
Breast CancerColorectal CancerExtrahepatic Bile Duct Cancer+9 more
Duke University 24
Testing effectiveness (Phase 2)Ended earlyNCT01185509
What this trial is testing

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 31
Early research (Phase 1)Looking for participantsNCT07029399
What this trial is testing

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more
NiKang Therapeutics, Inc. 361
Early research (Phase 1)Study completedNCT04818632
What this trial is testing

AZD9833 China PK Study

Who this might be right for
ER+, HER2-, Metastatic Breast Cancer
AstraZeneca 28
Not applicableStudy completedNCT07086196
What this trial is testing

Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 350
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Testing effectiveness (Phase 2)Looking for participantsNCT05377996
What this trial is testing

Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Who this might be right for
Triple Negative Breast CancerBreast CancerEndometrial Cancer+4 more
Day One Biopharmaceuticals, Inc. 360
Next Page